Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

By C. Chung, B. Mirakhur, E. Chan, Quynh-Thu Le, J. Berlin, M. Morse, B. Murphy, S. Satinover, J. Hosen, D. Mauro and 6 more. New England Journal of Medicine, 2008

1,137 citations recorded by the source corpus.

Subfields: Immunology, Immunology and Allergy, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/634c5fa699d3e94137f9c76bed2c72b5c48c44dd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. D. Wallace
2. L. Cox
3. J. Blessing-Moore
4. J. James
5. D. Bernstein
6. D. Ledford
7. P. Lieberman
8. D. Golden

Citations in the corpus

• The diagnosis and management of anaphylaxis practice parameter: 2010 update. (2010, background): “Cetuximab, a chimeric mouse/human IgG1 monoclonal antibody to epidermal growth factor receptor used in the treatment of colorectal cancer and squamous cell cancer of the head and neck has been associated with anaphylactic reactions.(256) A desensitization protocol has been developed for Cetuximab.”